Your Cart

Imagion Biosystems April 2022 Investor Newsletter

Imagion Biosystems April 2022 Investor Newsletter

We are pleased to provide our investors with our April 2022 Investor Newsletter.

In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap of his experience after visiting the San Diego office and additional company forethoughts.

We included a link back to our MagSense® HER2 breast cancer study update. You’ll also get an introduction to our Research Associate, Dan Inglese, and our newest Imagioneer, TJ Stalvey, who joins us as Senior Director of Clinical Operations.

We thank you for your continued support of our company and the work we are doing to develop our technology.

Imagion Biosystems normally distributes this update as an e-newsletter. Investors can sign up to receive email updates at THIS LINK.

Please click to review the newsletter.

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.